Tag: Heart Failure

Prescription rates increased from 2021 to 2023, but high variance seen between hospitals in the rate of prescriptions

Findings seen in patients with severe secondary tricuspid regurgitation of undefined etiology

Lower risk for composite of death from cardiovascular causes or worsening heart failure seen with tirzepatide versus placebo

Authors recommend patient and physician education and changes to practice guidelines and payment to overcome barriers to palliative care use

1,188,277 deaths could potentially be prevented over 12 months with optimal implementation of quadruple guideline-directed medical therapy

Prevalence expected to continue increasing and reach 11.4 million in 2050; lifetime risk for heart failure up to 24 percent

Long-term finerenone extends event-free survival up to three years for heart failure with mildly reduced or preserved ejection fraction

Improvement seen in aortic function, with significantly reduced augmentation index and pulse wave velocity and increased compliance

Reduced risk seen for total hospitalizations for heart failure, total adverse events of heart failure or all-cause mortality

MACE, heart failure composite end point, cardiovascular death, and all-cause death all improved with semaglutide for patients with versus without heart failure